# Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

> **NCT01824303** · PHASE2 · TERMINATED · sponsor: **Allergan** · enrollment: 31 (actual)

## Conditions studied

- Interstitial Cystitis

## Interventions

- **DRUG:** LiRIS 400 mg
- **OTHER:** LiRIS Placebo

## Key facts

- **NCT ID:** NCT01824303
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03
- **Primary completion:** 2014-11
- **Final completion:** 2014-12
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** This study was terminated early due to company decision.
- **Last updated:** 2016-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01824303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01824303, "Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01824303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*